Clinical Trial

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study. The secondary objectives are to assess pharmacokinetics and preliminary antitumor activity.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-04-28; most recent amendment 2026-04-15.
Trial Details
NCT Number NCT06959706
Lead Sponsor Tagworks Pharmaceuticals BV
Conditions Advanced Solid Tumors
Enrollment 50 participants
Start Date 2025-05-07
Primary Completion 2026-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-04-16